GLI2-Driven Tumor Immune Evasion: Mechanisms and Research Implications

Study Background and Research Question

Immune checkpoint blockade (ICB) has transformed cancer therapy, offering durable responses in a subset of patients. However, primary and adaptive resistance to ICB remain significant obstacles, particularly in cancers exhibiting mesenchymal transformation—a process linked to poor prognosis and immunotherapy failure. The mechanisms underlying this resistance are complex and incompletely understood. Recent attention has focused on the tumor microenvironment (TME), where immune suppressive factors and stromal reprogramming blunt the effectiveness of immunotherapeutic approaches. The reference study by DeVito et al. (Cancer Res. 2025, 85(9):1644–1662) addresses a critical gap: the molecular drivers linking mesenchymal transformation to immune evasion and resistance, with a particular focus on the Hedgehog (HH) pathway transcription factor GLI2.

Key Innovation from the Reference Study

The central innovation reported by DeVito et al. is the identification of GLI2 as a pivotal orchestrator of tumor immune evasion and immunotherapeutic resistance during mesenchymal transformation. By integrating mechanistic, in vivo, and translational analyses, the authors demonstrate that GLI2 operates at a nexus between canonical HH signaling and non-canonical pathways (including TGFβ and hypoxia), driving a tolerogenic TME through the upregulation of WNT ligand production and increased prostaglandin synthesis. This dual coordination links developmental signaling with immune escape, providing a coherent mechanistic explanation for the observed resistance to anti-PD-1 immunotherapy in mesenchymal-like tumors. Importantly, the study reveals that pharmacologic disruption of either WNT or prostaglandin signaling can partially restore anti-tumor immunity and sensitize tumors to ICB.

Methods and Experimental Design Insights

The research employed a combination of genetic, pharmacological, and immunological techniques to dissect the role of GLI2:

• Genetic Manipulation: Tumor cell lines were engineered to overexpress or knock down GLI2, allowing direct assessment of its impact on immune modulation and therapy resistance.
• In Vivo Tumor Models: Both autochthonous and transplantation models of melanoma and non-small cell lung cancer were used to evaluate how GLI2 expression shapes the TME and influences response to anti-PD-1 therapy.
• Immune Profiling: Flow cytometry and immunohistochemistry characterized the infiltration and function of key immune cell subsets, including granulocytic myeloid-derived suppressor cells (PMN-MDSCs), conventional dendritic cells, CD8+ T cells, and natural killer cells.
• Pharmacological Inhibition: Selective inhibitors of EP2/EP4 prostaglandin receptors and WNT ligand secretion were deployed to test whether blocking downstream GLI2 effectors could reverse immune evasion and overcome therapeutic resistance.
• Translational Correlation: Publicly available transcriptomic datasets from stage IV melanoma patients treated with anti-PD-1 antibodies were analyzed to correlate GLI2 expression signatures with clinical resistance.

This multifaceted approach enabled robust mechanistic dissection and supported the translational relevance of the findings.

Core Findings and Why They Matter

The study provides several major insights:

• GLI2 as a Central Node in Immune Evasion: GLI2 upregulation in tumor cells induces production of WNT ligands and prostaglandins, which jointly promote an immunosuppressive microenvironment.
• Recruitment of Suppressive Myeloid Cells: Enhanced WNT and prostaglandin signaling drives the accumulation and activity of PMN-MDSCs, which dampen anti-tumor responses by secreting TGFβ and nitric oxide and by inhibiting dendritic cell and cytotoxic lymphocyte function.
• Therapeutic Resistance: Tumors with high GLI2 activity are resistant to anti-PD-1 therapy, consistent with clinical observations that mesenchymal transformation predicts poor ICB response.
• Targetable Pathways: Pharmacological inhibition of the EP2/EP4 prostaglandin receptors or WNT ligand secretion can partially reverse immune suppression and sensitize tumors to ICB. Notably, a GLI2-associated transcriptional signature correlates with resistance in patient samples, highlighting the clinical relevance.

These findings suggest that GLI2 integrates multiple signaling axes to enforce immune tolerance, placing it as a promising target for combination immunotherapy strategies.

Comparison with Existing Internal Articles

Several recent reviews and research guides highlight the translational significance of GLI inhibitors such as GANT61 for dissecting HH pathway function and overcoming therapy resistance:

• The article "GLI Inhibitors in Cancer: Translating Mechanisms to Therapies" underscores the value of selective GLI antagonists in probing mechanisms of tumor growth, immune escape, and resistance. The present study by DeVito et al. provides direct mechanistic evidence for these concepts, showing that GLI2-driven transcriptional programs can be pharmacologically targeted to modulate the TME.
• "GANT61: Selective GLI Transcription Factor Inhibitor for Tumor Growth Suppression" discusses preclinical models where GANT61 disrupts GLI-driven oncogenic signaling. The new evidence places this class of compounds in a broader immunological context, linking GLI transcriptional activity to immune checkpoint resistance.
• Workflow-oriented resources such as "GANT61: GLI Inhibitor Workflows for Tumor Growth Suppression" offer practical guidance for integrating GLI inhibition into experimental pipelines, complementing the mechanistic findings by DeVito et al. with scenario-driven recommendations.

Collectively, these resources and the reference paper converge on the importance of GLI-mediated transcription inhibition in both the fundamental understanding of tumor biology and the practical development of combination therapies.

Limitations and Transferability

While the study robustly implicates GLI2 in immune evasion and ICB resistance, several caveats warrant consideration:

• Model Specificity: Most mechanistic data were generated in melanoma and non-small cell lung cancer models. The extent to which GLI2-driven immune suppression operates across diverse tumor types remains to be fully elucidated.
• Partial Reversal with Single Pathway Blockade: Inhibition of either WNT or prostaglandin signaling reversed only subsets of the immunosuppressive effects, suggesting that effective reversal may require multi-targeted approaches or direct GLI inhibition.
• Translational Correlation: Although a GLI2 transcriptional signature correlates with resistance in patient datasets, prospective clinical validation is needed to confirm predictive value and therapeutic benefit.
• Pharmacological Tools: The study primarily used inhibitors of downstream pathways; direct pharmacological inhibition of GLI2, for example with a selective small-molecule GLI inhibitor, was not tested in this context.

These limitations highlight both the promise and the need for further experimental and clinical research to optimize strategies targeting the GLI2-WNT-prostaglandin axis.

Protocol Parameters

• GLI2 modulation: Utilize genetic overexpression or knockdown in tumor cell lines to assess immune modulatory effects.
• Inhibitor dosing: Follow established preclinical regimens for WNT pathway or prostaglandin receptor inhibitors; for GLI inhibitors like GANT61, in vivo protocols often employ 50 mg/kg intraperitoneally or subcutaneously, as reported in the product information.
• Immune profiling: Apply multi-parameter flow cytometry for TME characterization, including MDSC, dendritic cell, and T lymphocyte subsets.
• Translational correlation: Integrate analysis of patient-derived transcriptomic data to explore clinical relevance of GLI2 signatures.
• Workflow optimization: Refer to scenario-driven guides for best practices in GLI inhibitor experiments, as outlined in reliable workflow resources.

Research Support Resources

For researchers aiming to experimentally target the GLI2 axis in cancer models, GANT61 (SKU A1615) is a well-characterized selective small-molecule antagonist of GLI transcription factors. It effectively blocks GLI1/2-mediated transcription (IC₅₀ ≈ 5 μM) and has demonstrated tumor growth suppression and induction of cell cycle arrest in preclinical models, including neuroblastoma xenografts. Protocols recommend dosing regimens such as 50 mg/kg intraperitoneally or subcutaneously and highlight the importance of solvent choice and storage conditions for optimal solubility and activity. Researchers can integrate GANT61 into workflows to study GLI-mediated transcription inhibition and its impact on tumor immune evasion, as supported by both product data and recent literature. Additional scenario-driven guidance can be found in specialized workflow articles. For procurement and specifications, consult APExBIO's product page.